Hypoxia in the androgen-dependent shionogi model for prostate cancer at three stages

Radiation Research

Volumn 162, Issue 5, 2004, Pages 547-553

  Skov, Kirsten ^a   Adomat, Hans ^a   Bowden, Mary ^b   Dragowska, Wieslawa ^c   Gleave, Martin ^b   Koch, Cameron J ^c   Woo, Janet ^a   Yapp, Donald T T ^a,d  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 NITRO 1H IMIDAZOL 1 YL) N (2,2,3,3,3 PENTAFLUOROPROPYL)ACETAMIDE; ANDROGEN; CELL MARKER; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY ELK3 51; UNCLASSIFIED DRUG;

ANDROGEN METABOLISM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BINDING AFFINITY; CANCER RADIOTHERAPY; CANCER STAGING; CASTRATION; CELL HYPOXIA; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; FLOW CYTOMETRY; FROZEN SECTION; HORMONE RESISTANCE; HYPOXIC CELL; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RADIATION RESPONSE; STATISTICAL SIGNIFICANCE; TUMOR REGRESSION;

ANDROGENS; ANIMALS; ANOXIA; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FLOW CYTOMETRY; IMAGE CYTOMETRY; MALE; MAMMARY NEOPLASMS, ANIMAL; MICE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; NEOPLASMS, HORMONE-DEPENDENT; NITROIMIDAZOLES; PROGNOSIS; PROSTATIC NEOPLASMS; PROTEIN BINDING; TIME FACTORS; TUMOR BURDEN;

MURINAE;

EID: 10044247472     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.1667/RR3254     Document Type: Conference Paper

References (49)

1. J. C. Mottram, Factor of importance in radiosensitivity of tumours. Br. J. Radiol. 9, 606-614 (1936).
2. J. Brown and A. J. Giaccia, Tumour hypoxia: The picture has changed in the 1990's. Int. J Radiat. Biol. 65, 95-102 (1994).
3. I. Tannock, Response of aerobic and hypoxic cells in a solid tumor to Adriamycin and cyclophosphamide and interaction of the drugs with radiation. Cancer Res. 42, 4921-4926 (1982).
4. L. H. Gray, A. D. Conger, M. Ebert, S. Hornsey and O. C. A. Scott, The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br. J. Radiol. 26, 638-648 (1953).
5. D. M. Brizel, S. P. Scully, J. M. Harrelson, L. J. Layfield, J. M. Bean, L. R. Prosnitz and M. W. Dewhirst, Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 56, 941-943 (1996).
6. M. Hockel, K. Schlenger, B. Aral, M. Mitze, U. Schaffer and P. Vaupel, Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 56, 4509-4515 (1996).
7. D. M. Brizel, G. S. Sibley, L. R. Prosnitz, R. L. Scher and M. W. Dewhirst, Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 38, 285-289 (1997).
8. 18F]fluoromisonidazole: A pretherapy study of 37 patients. Int. J. Radiat. Oncol. Biol. Phys. 36, 417-428 (1996).
9. 2 ratio predicts for biochemical failure in patients with prostate cancer: Preliminary findings. Urology 60, 634-639 (2002).
10. 2 study. Am. J. Clin. Oncol. 24, 458-461 (2001).
11. 2 study. Cancer 89, 2018-2024 (2000).
12. G. W. Chodak, T. Keane and L. Klotz, Critical evaluation of hormonal therapy for carcinoma of the prostate. Urology 60, 201-208 (2002).
13. M. Bolla, D. Gonzalez, P. Warde, J. B. Dubois, R. O. Mirimanoff, G. Storme, J. Bernier, A. Kuten, C. Sternberg, T. Gil, L. Collette and M. Pierart, Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N. Engl. J. Med. 337, 295-300 (1997).
14. M. V. Pilepich, J. M. Krall, M. al-Sarraf, M. J. John, R. L. Doggett, W. T. Sause, C. A. Lawton, R. A. Abrams and M. Rotman, Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the Radiation Therapy Oncology Group. Urology 45, 616-623 (1995).
15. M. V. Pilepich, K. Winter, M. J. John, J. B. Mesic, W. Sause, P. Rubin, C. Lawton, M. Machtay and D. Grignon, Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 50, 1243-1252 (2001).
16. D. M. Brizel, S. P. Scully, J. M. Harrelson, L. J. Layfield, J. M. Bean, L. R. Prosnitz and M. W. Dewhirst, Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 56, 941-943 (1996).
17. R. K. Wong, A. Fyles, M. Milosevic, M. Pintilie and R. P. Hill, Heterogeneity of polarographic oxygen tension measurements in cervix cancer: an evaluation of within and between tumor variability, probe position, and track depth. Int. J. Radiat. Oncol. Biol. Phys. 39, 405-412 (1997).
18. P. Olive, T. Trotter, J. P. Banath, S. M. Jackson and J. Le Riche, Heterogeneity in human tumour hypoxic fraction using the comet assay. Br. J. Cancer 74, S191-S195 (1996).
19. 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J. Nucl. Med. 40, 177-183 (1999).
20. J. A. Raleigh, J. K. La Dine, J. M. Cline and D. E. Thrall, An enzyme-linked immunosorbent assay for hypoxia marker binding in tumours. Br. J. Cancer 69, 66-71 (1994).
21. R. Urtasun, M. B. Parliament, A. J. McEwan, J. R. Mercer, R. H. Mannan, L. I. Wiebe, C. Morin and J. D. Chapman, Measurement of hypoxia in human tumours by non-invasive SPECT imaging of iodoazomycin arabinoside. Br. J. Cancer 74, S209-S212 (1996).
22. C. J. Koch and S. M. Evans, Non-invasive PET and SPECT imaging of tissue hypoxia using isotopically labeled 2-nitroimidazoles. Adv. Exp. Med. Biol. 510, 285-292 (2003).
23. C. J. Koch, Measurement of absolute oxygen levels in cells and tissues using oxygen sensors and 2-nitroimidazole EF5. Meth. Enzymol. 352, 3-31 (2002).
24. 18F-EF5. Eur. J. Nucl. Med. Mol. Imaging 30, 259-266 (2003).
25. T. Minesita and K. Yamaguchi, An androgen-dependent mouse mammary tumor. Cancer Res. 25, 1168-1175 (1965).
26. H. Miyake, A. Tolcher and M. E. Gleave, Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model. Cancer Res. 59, 4030-4034 (1999).
27. P. S. Rennie, N. Bruchovsky, R. Buttyan, M. Benson and H. Cheng, Gene expression during the early phases of regression of the androgen-dependent Shionogi mouse mammary carcinoma. Cancer Res. 48, 6309-6312 (1988).
28. H. Miyake, M. Pollak and M. E. Gleave, Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models. Cancer Res. 60, 3058-3064 (2000).
29. T. Nickerson, H. Miyake, M. E. Gleave and M. Pollak, Castration-induced apoptosis of androgen-dependent Shionogi carcinoma is associated with increased expression of genes encoding insulin-like growth factor-binding proteins. Cancer Res. 59, 3392-3395 (1999).
30. N. Bruchovsky and P. S. Rennie, Classification of dependent and autonomous variants of Shionogi mammary carcinoma based on heterogenous patterns of androgen binding. Cell 13, 273-280 (1978).
31. A. L. Zietman, E. A. Prince, B. M. Nakfoor and J. J. Park, Androgen deprivation and radiation therapy: Sequencing studies using the Shionogi in vivo tumor system. Int. J. Radiat. Oncol. Biol. Phys. 38, 1067-1070 (1997).
32. A. L. Zietman, B. M. Nakfoor, E. A. Prince and L. E. Gerweck, The effect of androgen deprivation and radiation therapy on an androgen-sensitive murine tumor: An in vitro and in vivo study. Cancer J. Sci. Am. 3, 31-36 (1997).
33. C. M. Ludgate, J. T. Lim, A. G. Wilson, A. S. Alexander and K. S. Wilson, Neoadjuvant hormone therapy and external beam radiation for localized prostate cancer: Vancouver Island Cancer Centre experience. Can. J. Urol. 7, 937-943 (2000).
34. Y. Xiong, G. J. Hannon, H. Zhang, D. Casso, R. Kobayashi and D. Beach, p21 is a universal inhibitor of cyclin kinases. Nature 366, 701-704 (1993).
35. S. M. Evans, B. Joiner, W. T. Jenkins, K. M. Laughlin, E. M. Lord and C. J. Koch, Identification of hypoxia in cells and tissues of epigastric 9L rat glioma using EF5 (2-[2-nitro-]H-imidazol-1-yl]-N-(2,2,3,3,3-pentafluoropropyl) acetamide). Br. J. Cancer 72, 825-882 (1995).
36. C. J. Koch, S. M. Evans and E. M. Lord, Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-]H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide]: Analysis of drug adducts by fluorescent antibodies vs bound radioactivity. Br. J. Cancer 72, 869-874 (1995).
37. E. M. Lord, L. Harwell and C. J. Koch, Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts. Cancer Res. 53, 5721-5726 (1993).
38. A. Field, Discovering Statistics: Using SPSS for Windows. SAGE Publications, London, 2000.
39. IAEA, Predictive Assays and their Role in Selection of Radiation as the Therapeutic Modality. TECDOC-1297, International Atomic Energy Agency, Vienna, Austria, 2002.
40. J. M. Brown and A. J. Giaccia, The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy. Cancer Res. 58, 1408-1416 (1998).
41. M. Hockel and P. Vaupel, Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. J. Natl. Cancer Inst. 93, 266-276 (2001).
42. H. Miyake, C. Nelson, P. S. Rennie and M. E. Gleave, Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. Cancer Res. 60, 2547-2554 (2000).
43. C. N. Coleman, J. B. Mitchell and K. Camphausen, Tumor hypoxia: chicken, egg, or a piece of the farm? J. Clin. Oncol. 20, 610-615 (2001).
44. 18F]-EF5, a marker for PET detection of hypoxia: Synthesis of precursor and a new fluorination procedure. Appl. Radiat. Isot. 54, 73-80 (2001).
45. N. Oyama, J. Kim, L. A. Jones, N. M. Mercer, J. A. Engelbach, T. L. Sharp and M. J. Welch, MicroPET assessment of androgenic control of glucose and acetate uptake in the rat prostate and a prostate cancer tumor model. Nucl. Med. Biol. 29, 783-790 (2002).
46. 31P nuclear magnetic resonance spectroscopy: A review. Cancer Res. 49, 4075-4085 (1989).
47. I. Tropres, S. Grimault, A. Vaeth, E. Grillon, C. Julien, J. F. Payen, L. Lamalle and M. Decorps, Vessel size imaging. Magn. Reson. Med. 45, 397-408 (2001).
48. 31P-MRS measurements of extracellular pH of tumors using 3-aminopropylphosphonate. Am. J. Physiol. 267, C195-203 (1994).
49. 31P NMR. Proc. Natl. Acad. Sci. USA 80, 2748-2751 (1983).